DOCSLIB.ORG

HPHC Utilization Management Review Criteria 6.16.2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HPHC Utilization Management Review Criteria 6.16.2020 Utilization Management Review Criteria Reference #: DD 2024-H1 Signature/Date/Last Approved: Rick J. Dean, 7/16/2019 Department/Approved By: Organization Wide, CEO Effective: 12/10/2014 Copyright © Oncology Analytics, Inc. All rights reserved. Last Revised: 7/16/2019 Purpose: To explicitly state the criteria on which reviews are based. Process: Oncology Analytics Inc. (OA) evaluates the management of cancer patients receiving cancer chemotherapy and associated treatments, including radiation, biologic and gene therapy. To properly perform this function, OA evaluates the medical literature and reviews national guideline and compendia recommendations. Based on this information, OA has developed a database comprised of treatment protocols. Treating physicians and supportive staff assign the appropriate chemotherapy ± supportive agent protocol(s) to patients to initiate prior authorization requests. OA’s clinical staff maintains the database. The OA clinical staff, comprised of board-certified hematologists/medical oncologists and board-certified oncology pharmacists, review the database at least annually and update the protocols as necessary. OA recognizes that the field of oncology is changing rapidly. Accordingly, new protocols are evaluated and added to the database on an ongoing basis. The following highlights the criteria on which protocol reviews for adult oncology patients are based: • New drugs or regimens (combinations of drugs) approved by the FDA (on-label use) • Drugs or regimens may be used off-label (without FDA approval) and considered medically accepted if supported by any of the following compendia below and not listed as unsupported, not indicated, or not recommended within any compendia below. o NCCN Drugs & Biologics Compendium® § Category 1-2A recommendations are considered medically accepted uses § Category 2B recommendations will be considered if identified as medically accepted in an alternative compendium or supported by peer-reviewed scientific literature eligible for coverage (meeting abstracts and case reports are excluded from consideration) § Category 3 listings are considered not medically accepted uses • OA subscribes to the NCCN Flash Updates™, which informs OA when NCCN Guidelines® and the NCCN Drugs & Biologics Compendium® are updated o Clinical Pharmacology § Medically accepted uses are identified by narrative text is supportive § Not medically accepted uses are identified by narrative text that is “not supportive.” o American Hospital Formulary Service-Drug Information (AHFS-DI) 2 | Page Copyright © 2020 Oncology Analytics, Inc. All rights reserved § Medically accepted uses are identified by narrative text is supportive § Not medically accepted uses are identified by narrative text that is “not supportive.” o Thompson Micromedex DrugDex® § Class I, IIA, or IIb recommendations are considered medically accepted uses § Class III listings are considered not medically accepted uses o Wolters Kluwer Lexi-Drugs® § Medically accepted uses are identified by an indication listed as “Use: Off-Label” and rated as “Evidence Level A” § Not medically accepted uses are those indications listed as “Use: Unsupported” • Off-label use of drugs or regimens may also be considered medically accepted if supported as safe and effective according to peer-reviewed scientific literature eligible for coverage from one of the following publications: o American Journal of Medicine; o Annals of Internal Medicine; o Annals of Oncology; o Annals of Surgical Oncology; o Biology of Blood and Marrow Transplantation; o Blood; o Bone Marrow Transplantation; o British Journal of Cancer; o British Journal of Hematology; o British Medical Journal; o Cancer; o Clinical Cancer Research; o Drugs; o European Journal of Cancer (formerly the European Journal of Cancer and Clinical Oncology); o Gynecologic Oncology; o International Journal of Radiation, Oncology, Biology, and Physics; o The Journal of the American Medical Association; o Journal of Clinical Oncology; o Journal of the National Cancer Institute; o Journal of the National Comprehensive Cancer Network (NCCN); o Journal of Urology; o Lancet; o Lancet Oncology; o Leukemia; o The New England Journal of Medicine; or o Radiation Oncology § Meeting abstracts and case reports are excluded from consideration • Coverage determination may also be directed by the Centers of Medicare & Medicaid Services (CMS) National Coverage Determinations (NCD) or Local Coverage Determinations (LCD), state- specific Medicaid drug utilization requirements, and/or health plan specific drug coverage policies, where applicable. 3 | Page Copyright © 2020 Oncology Analytics, Inc. All rights reserved • Unique cases that do not fit standard criteria o Non-standard protocols may be approved based on unique clinical circumstances, especially for rare diseases which may lack guideline-based treatment recommendations. o Non-standard protocols are entered into the database as needed. In addition, any practicing oncologist can request that a protocol be added to the database. Also, based on ongoing reviews of the medical literature and the ASCO and NCCN guidelines, obsolete treatment protocols are inactivated making them no longer available for view by the treating party. Table 1: This policy applies to the following agents that require prior authorization: Generic Name HCPCS ado-trastuzumab emtansine J9354 aldesleukin J9015 amifostine crystalline J0207 aprepitant J0185 arsenic trioxide J9017 asparaginase (Erwinia chrysanthemi) J9019 atezolizumab J9022 avelumab J9023 Axicabtagene ciloleucel Q2041 azacitidine J9025 BCG live J9030 belinostat J9032 bendamustine inj, 1 MG J9033 bendeka, 1 mg J9034 belrapzo inj, 1 mg J9036 bevacizumab J9035 bevacizumab-awwb Q5107 bevacizumab-bvzr Q5118 bleomycin sulfate J9040 blinatumomab J9039 bortezomib J9041 bortezomib J9044 brentuximab vedotin J9042 busulfan J0594 cabazitaxel J9043 calaspargase pegol-mknl J9118 carboplatin J9045 4 | Page Copyright © 2020 Oncology Analytics, Inc. All rights reserved carfilzomib J9047 carmustine J9050 cemiplimab-rwlc J9119 cetuximab J9055 cisplatin J9060 cladribine J9065 clofarabine J9027 copanlisib di-HCl J9057 cyclophosphamide J9070 cytarabine J9100 cytarabine liposome/PF J9098 dacarbazine J9130 dactinomycin J9120 daratumumab J9145 darbepoetin alfa J0881 daunorubicin citrate liposomal J9151 daunorubicin HCl J9150 daunorubicin/cytarabine liposomal J9153 decitabine J0894 degarelix acetate J9155 denileukin diftitox J9160 denosumab J0897 dexrazoxane HCl J1190 docetaxel J9171 dolasetron mesylate J1260 doxorubicin HCl J9000 doxorubicin HCl pegylated liposomal Q2049 doxorubicin HCl pegylated liposomal Q2050 durvalumab J9173 elotuzumab J9176 enfortumab vedotin-ejfv J9999 epirubicin HCl J9178 epoetin alfa J0885 epoetin alfa-epbx Q5106 eribulin mesylate J9179 etoposide J9181 etoposide phosphate J9181 fam-trastuzumab deruxtecan-nxki J9999 filgrastim J1442 filgrastim-aafi Q5110 filgrastim-sndz Q5101 floxuridine J9200 5 | Page Copyright © 2020 Oncology Analytics, Inc. All rights reserved fludarabine phosphate J9185 fluorouracil J9190 fosaprepitant dimeglumine J1453 fosnetupitant chloride HCl/palonosetron HCl J1454 fulvestrant J9395 gemcitabine HCl J9201 gemcitabine HCl (Infugem) J9201 gemtuzumab ozogamicin J9203 goserelin acetate J9202 granisetron J1627 granisetron HCl J1626 histrelin acetate J9225 idarubicin HCl J9211 ifosfamide J9208 immune globulin J1560 immune globulin J1566 immune globulin J1555 immune globulin J1569 immune globulin J1568 immune globulin J1557 immune globulin J1459 immune globulin J1559 immune globulin J1572 immune globulin J1561 immune globulin J1575 immune globulin J1460 immune globulin J3590 inotuzumab ozogamicin J9229 interferon alfa-2b,recomb. J9214 interferon gamma-1b,recomb. J9216 iobenguane iodine 131 A9699 ipilimumab J9228 irinotecan HCl J9206 irinotecan liposomal J9205 isatuximab-irfc J9999 ixabepilone J9207 kit for prep yttrium-90/ibritumomab tiuxetan/albumin human A9543 lanreotide acetate J1930 leucovorin calcium J0640 levoleucovorin J0642 levoleucovorin calcium J0641 6 | Page Copyright © 2020 Oncology Analytics, Inc. All rights reserved leuprolide acetate J1950 leuprolide acetate J9217 leuprolide acetate J9218 leuprolide acetate/lidocaine HCl J9219 lutetium Lu 177 dotatae A9513 lymphocyte IG,antithymocyt,equ/thimerosal J7504 mechlorethamine HCl J9230 melphalan HCl J9245 melphalan HCl/betadex sulfobutyl ether sodium J9245 mesna J9209 methotrexate sodium J9250 methotrexate sodium J9260 mitomycin J9280 mitoxantrone HCl J9293 mogamulizumab-kpkc J9204 moxetumomab pasudotox-tdfk J9313 nab-paclitaxel J9264 necitumumab J9295 Netuiptant/palonosetron J8655 nelarabine J9261 nivolumab J9299 obinutuzumab J9301 octreotide acetate J2354 octreotide acetate, microspheres J2353 ofatumumab J9302 olaratumab J9285 omacetaxine mepesuccinate J9262 oxaliplatin J9263 paclitaxel J9267 palifermin J2425 palonosetron J2469 pamidronate disodium J2430 panitumumab J9303 pegaspargase J9266 pegfilgrastim J2505 pegfilgrastim-apgf J3590 pegfilgrastim-bmez J3590 pegfilgrastim-cbqv Q5111 pegfilgrastim-jmdb Q5108 peginterferon alfa-2b J9999 pembrolizumab J9271 pemetrexed disodium J9305 7 | Page Copyright © 2020 Oncology Analytics, Inc. All rights reserved pentostatin J9268 pertuzumab J9306 plerixafor J2562 polatuzumab vedotin-piiq J9309 porfimer sodium J9600 pralatrexate J9307 radium-223 dichloride A9606 ramucirumab J9308 rasburicase J2783 rituximab J9312 rituximab-abbs Q5115 rituximab-pwr J9999 rituximab/hyaluronidase, human recombinant J9311 rolapitant HCl J2797
Load more

Recommended publications
  • = 'NH., Diseases, Central Nerrous System M)Ury and Different Foims of Mflannnation
    (12) INTERNATIONAL APPLICATION Pl;BLISHED 1. NDER THE PATENT COOPERATION TREATY (PCT) (19) World intellectual Property Organraation llIlllIlllIlIllllllllIlllllIIllIllIlllIlllllllllllIlllIllIlIlllIllIlIllIllIlIIIIIIIIIIIIIIIIIII International Bureau (10) International Publication Number (43) International Publication Date WO 2020/114892 Al 11 June 2020 (11.06.2020) W 4 P Gl I P 0 T (51) International Patent Classification: C07D 401/06 (200G 0 I) AGJK31/454 (200G 0l) C07D dt)J//4 (2006 01) A61P35/ttd (200G 0l) (21) International Application Number: PCT/EP2019/l)8 3014 (22) International Filing Date: 29 Nosember 2019 (29.11.2019) (25) Filing Language: Enghsh (26) Publication Language Enghsh (30) Priority Data: 1820972/i 1 03 December 20)8 (03 12 2018) EP (71) Applicant: MERCK PATENT GMBH IDE/DE]. Frm&(s- furter Strasse 230. 64293 DARMSTADT (DE) (72) Inventors: BUCHSTALLER, Hans-Peter. Ncc)sa&strasse G. G4347 GRIESHELVI (DE). ROHDICH, Feliru Saalbaus- tmssc 23. 64283 DARMSTADT (DE). (81) Designated States /unless i&themmse n&d&ct&md, /or e&ery hind of national protect«&n menial&le/ AF, AG, AL, AVI AO, AT. AU. AZ, BA, BB, BG, BH. B N. BR, BW, BY. BZ. CA. CH, CL, CN. CO, CR. C U, CZ. DE, DJ, DK. DM DO. DZ, EC. EE, EG. ES. FI, GB. GD. GE. GH, GM. GT. HN. HR. HU, ID, IL. IN, IR, IS. JO, JP, KE. KG, KH. KN, KP. KR. KW, KZ, LA. L C, LK. LR, LS, LU. LY. MA. MD, ME. WIG. MK. MN, MW, MX. MY. MZ. NA. NG. NI, NO. NZ. OM, PA. PE, PG. PH, PL. PT. QA, RO, RS.
    [Show full text]
  • WO 2018/223101 Al 06 December 2018 (06.12.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/223101 Al 06 December 2018 (06.12.2018) W !P O PCT (51) International Patent Classification: (71) Applicant: JUNO THERAPEUTICS, INC. [US/US]; 400 A 61K 35/1 7 (20 15.0 1) A 61P 35/00 (2006 .0 1) Dexter Ave. N., Suite 1200, Seattle, WA 98109 (US). (21) International Application Number: (72) Inventor: ALBERTSON, Tina; 400 Dexter Ave. N., Suite PCT/US2018/035755 1200, Seattle, WA 98109 (US). (22) International Filing Date: (74) Agent: AHN, Sejin et al; Morrison & Foerster LLP, 1253 1 0 1 June 2018 (01 .06.2018) High Bluff Drive, Suite 100, San Diego, CA 92130-2040 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/5 14,774 02 June 2017 (02.06.2017) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/5 15,530 05 June 2017 (05.06.2017) US DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/521,366 16 June 2017 (16.06.2017) u s HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/527,000 29 June 2017 (29.06.2017) u s KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/549,938 24 August 2017 (24.08.2017) u s MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/580,425 0 1 November 2017 (01 .11.2017) u s OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/593,871 0 1 December 2017 (01 .12.2017) u s SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 62/596,764 08 December 2017 (08.12.2017) u s TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Assessment of Overall Survival, Quality of Life, And
    Supplementary Online Content Salas-Vega S, Iliopoulos O, Mossialos E. Assesment of overall survival, quality of life, and safety benefits associated with new cancer medicines [published online December 29, 2016]. JAMA Oncol. doi:10.1001/jamaoncol.2016.4166 eTable 1. Therapeutic profile of all cancer medicines approved by the FDA between 2003- 2013 eTable 2. Regulatory evidence in support of classification of drug clinical benefits eFigure 1. Number of cancer drugs that were evaluated by all three HTA agencies, sorted by magnitude of clinical benefits eTable 3. Interagency agreement–Krippendorff’s alpha coefficients eMethods This supplementary material has been provided by the authors to give readers additional information about their work. Online-Only Supplement © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/25/2021 Clinical value of cancer medicines Contents eExhibits ......................................................................................................................................................... 3 eTable 1. Therapeutic profile of all cancer medicines approved by the FDA between 2003- 2013 (Summary of eTable 2) ................................................................................................................... 3 eTable 2. Regulatory evidence in support of classification of drug clinical benefits ....................... 6 eFigure 1. Number of cancer drugs that were evaluated by all three HTA agencies, sorted by magnitude of clinical benefits
    [Show full text]
  • Press Release
    Press Release Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo’s HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201) Collaboration combines Daiichi Sankyo’s scientific and technological excellence with AstraZeneca’s global experience and resources in oncology to accelerate and expand the potential of [fam-] trastuzumab deruxtecan as monotherapy and combination therapy across a spectrum of HER2 expressing cancers AstraZeneca to pay Daiichi Sankyo up to $6.90 billion in total consideration, including $1.35 billion upfront payment and up to an additional $5.55 billion contingent upon achievement of future regulatory and sales milestones as well as other contingencies Companies to share equally development and commercialization costs as well as profits worldwide from [fam-] trastuzumab deruxtecan with Daiichi Sankyo maintaining exclusive rights in Japan Daiichi Sankyo is expected to book sales in U.S., certain countries in Europe, and certain other markets where Daiichi Sankyo has affiliates; AstraZeneca is expected to book sales in all other markets worldwide, including China, Australia, Canada and Russia Tokyo, Munich and Basking Ridge, NJ – (March 28, 2019) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it has entered into a global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s lead antibody drug conjugate (ADC), [fam-] trastuzumab deruxtecan (DS-8201), currently in pivotal development for multiple HER2 expressing cancers including breast and gastric cancer, and additional development in non-small cell lung and colorectal cancer. Daiichi Sankyo and AstraZeneca will jointly develop and commercialize [fam-] trastuzumab deruxtecan as a monotherapy or a combination therapy worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights.
    [Show full text]
  • Palifermin (Kepivance™) in the Treatment of Mucositis
    Session V • From cell biology to cell therapy Palifermin (Kepivance™) in the treatment of mucositis [haematologica reports] 2005;1(8):41-45 EMMANOUILIDES C n patients undergoing high dose chemo- factor (KGF) is a 28 kD member of the therapy and hematopoietic stem cell fibroblast growth factor family with epithe- Associate Profesor transplant, oral mucositis (OM) is one of lial cell proliferative properties.26 Palifermin of Medicine, UCLA, I Division Haematology-Oncology, the most debilitating and annoying side (Kepivance™) is a truncated, recombinant Thessaloniki, Greece effects. This complication results from form of human keratinocyte growth factor cytotoxic injury to the epithelial lining of (rHuKGF) that has been approved in the the oropharyngeal mucosa, although USA in 2004 to decrease the incidence and lesions of the whole gastrointestinal tract duration of severe OM in patients with also occur.1 The severity of OM varies from hematologic malignancies receiving myelo- erythema and edema accompanied by mild toxic therapy requiring HSCT support. Pal- soreness to full mucosal thickness ulcera- ifermin (recombinant human keratinocyte tions penetrating into the submucosa, growth factor) is an N-terminal, truncated often resulting in severe pain requiring version of endogenous keratinocyte growth narcotic analgesia and impaired swallow- factor with biologic activity similar to that ing, prolonged hospitalization, and of the native protein, but with increased increased risks for infections and poten- stability 26 In animal models of chemother- tially life-threatening sequelae.2,3 Between apy, radiotherapy, and hematopoietic stem- 40% to 80% of cancer patients undergo- cell transplantation27,28 palifermin protected ing intensive treatment regimens requiring several types of epithelial tissues.
    [Show full text]
  • Fam-Trastuzumab Deruxtecan-Nxki Submitted by Daiichi
    Dan Liang, PharmD Associate Director, Medical Information & Education Daiichi Sankyo, Inc. 211 Mount Airy Road Basking Ridge, NJ 07920 Phone: 908-992-7054 Email: [email protected] Date of request: July 9, 2020 NCCN Panel: Colon Cancer and Rectal Cancer On behalf of Daiichi Sankyo, Inc. and AstraZeneca Pharmaceuticals LP, I respectfully request the NCCN Guideline Panel for Colon and Rectal Cancers to review data from the clinical study1 in support of fam-trastuzumab deruxtecan-nxki, also known as T-DXd, as a monotherapy option for the treatment of patients with HER2-positive unresectable and/or metastatic colorectal cancer. Specific Changes: We respectfully ask the NCCN panel to consider the following: • COL-D1 through COL-D6 and REC-F1 through REC-F6, “Continuum of Care - Systemic Therapy for Advanced or Metastatic Disease” o Add “Fam-trastuzumab deruxtecan-nxki (HER2-positive and RAS and BRAF WT)” to the following: . COL-D1 and REC-F1: “Patient not appropriate for intensive therapy” . COL-D2 and REC-F2: “Previous oxaliplatin-based therapy without irinotecan” . COL-D3 and REC-F3: “Previous irinotecan-based therapy without oxaliplatin” . COL-D4 and REC-F4: “Previous treatment with oxaliplatin and irinotecan” . COL-D5 and REC-F5: “Previous therapy without irinotecan or oxaliplatin” . COL-D6 and REC-F6: “FOLFOX or CAPEOX or (FOLFOX or CAPEOX) + bevacizumab” • COL-D11 and REC-F11, “Systemic Therapy for Advanced or Metastatic Disease – Chemotherapy Regimens” o Add “Fam-trastuzumab deruxtecan-nxki 6.4 mg/kg IV on Day 1, cycled every 21 days” with a footnote: “fam-trastuzumab deruxtecan-nxki is approved for metastatic HER2-positive breast cancer at a different dose of 5.4 mg/kg IV on Day 1, cycled every 21 days” FDA Clearance: ENHERTU (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
    [Show full text]
  • Management of Multiple Myeloma: the Changing Paradigm
    Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Jeffrey A. Zonder, MD Karmanos Cancer Institute Objectives • Discuss use of standard myeloma therapies when used as therapy after relapse • Consider patient and disease factors which might impact therapy decisions. • Describe off-label options for patients who are not protocol candidates. Line ≠ Line ≠ Line ≠ … POLICE LINE – DO NOT CROSS POLICE LINE – DO NOT CROSS POLICE LINE – DO NOT CROSS POLICE LINE – DO NOT CROSS POLI LINE – DO NOT Define “Line” • A pre-defined course of therapy utilizing agents either simultaneously or sequentially – Len/Dex – Len/Dex ASCT – Vel/Dex ASCT Len/Dex – VDT-PACE ASCT TD ASCT VPT-PACE LD • Pts who have had the same # of “lines” of Rx may have had vastly different amounts of Rx What Is Relapsed/Refractory Disease? • Relapsed: recurrence after a response to therapy • Refractory: progression despite ongoing therapy What Do We Know About the Pt’s Myeloma? • What prior therapy has been used? • How well did it work? • Did the myeloma progress on active therapy? • High-risk cytogenetics/FISH/GEP? What Do We Know About the Patient? • Age • Other medical problems – Diabetes – Blood Clots • Lasting side effects from past therapies – Peripheral Neuropathy • Personal preferences and values Choosing Therapy for Relapsed/Refractory Myeloma Proteasome IMiDs Anthracyclines Alkylators Steroids HDACs Antibodies Inhibitors Thalidomide Bortezomib Doxil Melphalan Dex Panobinostat Elotuzumab Lenalidomide Carfilzomib Cytoxan Pred Vorinostat
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Advances in the Treatment of Hematologic Malignancies a Review of Newly Approved Drugs
    Advances in the Treatment of Hematologic Malignancies A Review of Newly Approved Drugs Katherine Shah, PharmD, BCOP Clinical Pharmacy Specialist, Hematology/Oncology Emory University Hospital / Winship Cancer Institute Disclosures • I do not (nor does any immediate family member have) a vested interest in or affiliation with any corporate organization offering financial support or grant monies for this continuing education activity or any affiliation with an organization whose philosophy could potentially bias my presentation • There was no financial support obtained for this CPE activity 1 Objectives • Discuss the pharmacologic principles of several new agents approved for use in hematologic malignancies – Drug class – Mechanism of action – Clinical trial highlights • Review approved dosing and recommend appropriate clinical monitoring and management of toxicities of new agents covered – Dosing recommendations for new agents – Side effect profile – Clinical management Approvals 1980‐2014 http://innovation.org/images/dmImage/SourceImage/lg_FDA_Approval.jpg 2 2014 Novel Drug Approvals Nature Reviews Drug Discovery 14, 77–81(2015) doi:10.1038/nrd4545 Select 2014 Novel Oncology Drugs Drug Indication Approval Date Siltuximab (Sylvant) Multicentric Castleman’s April 2014 Disease Belinostat (Beleodaq) Peripheral T‐cell Lymphoma July 2014 Idelalisib (Zydelig) CLL, Follicular NHL, SLL July 2014 Netupitant and Nausea/vomiting October 2014 palonosetron (Akynzeo) Blinatumomab Acute Lymphoblastic December 2014 (Blincyto) Leukemia, Ph‐ Ph-= Philadelphia
    [Show full text]
  • SYLVANT (Siltuximab) for Injection, for Intravenous Infusion Institute Prompt Anti-Infective Therapy and Do Not Administer Initial U.S
    ------------------------WARNINGS AND PRECAUTIONS----------------------- HIGHLIGHTS OF PRESCRIBING INFORMATION • Concurrent Active Severe Infections These highlights do not include all the information needed to use o Do not administer SYLVANT to patients with severe infections SYLVANT™ safely and effectively. See full prescribing information for until the infection resolves. (2) SYLVANT. o Monitor patients receiving SYLVANT closely for infections. SYLVANT (siltuximab) for Injection, for Intravenous infusion Institute prompt anti-infective therapy and do not administer Initial U.S. Approval: [yyyy] SYLVANT until the infection resolves. (2) ----------------------------INDICATIONS AND USAGE---------------------------- • Vaccinations: Do not administer live vaccines because IL-6 inhibition SYLVANT is an interleukin-6 (IL-6) antagonist indicated for the treatment of may interfere with the normal immune response to new antigens. (5.2) patients with multicentric Castleman’s disease (MCD) who are human • Infusion Related Reactions: Administer SYLVANT in a setting that immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) provides resuscitation equipment, medication, and personnel trained to negative. (1) provide resuscitation. (6.1) • Gastrointestinal (GI) perforation: Use with caution in patients who may Limitation of Use be at increased risk. Promptly evaluate patients presenting with SYLVANT was not studied in patients with MCD who are HIV positive or symptoms that may be associated or suggestive of GI perforation. (5.4) HHV-8 positive because SYLVANT did not bind to virally produced IL-6 in a nonclinical study. ------------------------------ADVERSE REACTIONS------------------------------- The most common adverse reactions (>10% compared to placebo) during -----------------------DOSAGE AND ADMINISTRATION----------------------- treatment with SYLVANT in the MCD clinical trial were pruritus, increased For intravenous infusion only. weight, rash, hyperuricemia, and upper respiratory tract infection.
    [Show full text]
  • Neuro-Ophthalmic Side Effects of Molecularly Targeted Cancer Drugs
    Eye (2018) 32, 287–301 © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0950-222X/18 www.nature.com/eye 1,2,3 4 Neuro-ophthalmic side MT Bhatti and AKS Salama REVIEW effects of molecularly targeted cancer drugs Abstract The past two decades has been an amazing time culminated in indescribable violence and in the advancement of cancer treatment. Mole- unspeakable death. However, amazingly within cularly targeted therapy is a concept in which the confines of war have risen some of the specific cellular molecules (overexpressed, greatest advancements in medicine. It is within mutationally activated, or selectively expressed this setting—in particular World War II with the proteins) are manipulated in an advantageous study of mustard gas—that the annals of cancer manner to decrease the transformation, prolif- chemotherapy began touching the lives of eration, and/or survival of cancer cells. In millions of people. It is estimated that in 2016, addition, increased knowledge of the role of the over 1.6 million people in the United States will immune system in carcinogenesis has led to the be diagnosed with cancer and over a half a development of immune checkpoint inhibitors million will die.1 The amount of money being to restore and enhance cellular-mediated anti- spent on research and development of new tumor immunity. The United States Food and cancer therapies is staggering with a record $43 Drug Administration approval of the chimeric billion dollars spent in 2014. Nearly 30% of all monoclonal antibody (mAb) rituximab in 1997 registered clinical trials on the clinicaltrials.gov 1Department of for the treatment of B cell non-Hodgkin lym- website pertain to cancer drugs.
    [Show full text]
  • Whither Radioimmunotherapy: to Be Or Not to Be? Damian J
    Published OnlineFirst April 20, 2017; DOI: 10.1158/0008-5472.CAN-16-2523 Cancer Perspective Research Whither Radioimmunotherapy: To Be or Not To Be? Damian J. Green1,2 and Oliver W. Press1,2,3 Abstract Therapy of cancer with radiolabeled monoclonal antibodies employing multistep "pretargeting" methods, particularly those has produced impressive results in preclinical experiments and in utilizing bispecific antibodies, have greatly enhanced the thera- clinical trials conducted in radiosensitive malignancies, particu- peutic efficacy of radioimmunotherapy and diminished its toxi- larly B-cell lymphomas. Two "first-generation," directly radiola- cities. The dramatically improved therapeutic index of bispecific beled anti-CD20 antibodies, 131iodine-tositumomab and 90yttri- antibody pretargeting appears to be sufficiently compelling to um-ibritumomab tiuxetan, were FDA-approved more than a justify human clinical trials and reinvigorate enthusiasm for decade ago but have been little utilized because of a variety of radioimmunotherapy in the treatment of malignancies, particu- medical, financial, and logistic obstacles. Newer technologies larly lymphomas. Cancer Res; 77(9); 1–6. Ó2017 AACR. "To be, or not to be, that is the question: Whether 'tis nobler in the pembrolizumab (anti-PD-1), which are not directly cytotoxic mind to suffer the slings and arrows of outrageous fortune, or to take for cancer cells but "release the brakes" on the immune system, arms against a sea of troubles, And by opposing end them." Hamlet. allowing cytotoxic T cells to be more effective at recognizing –William Shakespeare. and killing cancer cells. Outstanding results have already been demonstrated with checkpoint inhibiting antibodies even in far Introduction advanced refractory solid tumors including melanoma, lung cancer, Hodgkin lymphoma and are under study for a multi- Impact of monoclonal antibodies on the field of clinical tude of other malignancies (4–6).
    [Show full text]